Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? - Cancer Treatment Reviews
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study - ESMO Open
Frontiers | Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
Cancers | Free Full-Text | Immune Resistance and EGFR Antagonists in Colorectal Cancer | HTML
RAS and RAF mutation status in the selection of patients for anti-EGFR therapy | Colorectal Cancer
Colorectal Cancer: new Evidence about the predictive Value of Biomarkers
Identification of actionable alterations in colorectal cancer are leading to the development of novel treatment strategies - Mayo Clinic
Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution - ScienceDirect
Cancers | Free Full-Text | Immune Resistance and EGFR Antagonists in Colorectal Cancer | HTML
Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 1: Biologic Therapies Targeting the Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor
EGFR-mediated signaling pathways and mechanisms of anti-EGFR therapy.... | Download Scientific Diagram
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives - Annals of Oncology
Anti-EGFR agents used in mCRC | Download Scientific Diagram
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
![PDF] Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9ebf8b10a85fed17463aa14025921da954f7bec0/2-Figure1-1.png "PDF] Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer | Semantic Scholar")
PDF] Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer | Semantic Scholar
The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon | British Journal of Cancer
EGFR signaling in colorectal cancer: a clinical perspective | GICTT
No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer? - Annals of Oncology
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
Proposed working model. In MLH1(+) colon cancer cells, anti-EGFR... | Download Scientific Diagram
Figure 1 from Mechanisms of resistance to anti-EGFR therapy in colorectal cancer | Semantic Scholar
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies | Journal of Experimental & Clinical Cancer Research | Full Text
APMG Colon Molecular Pathways
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer - ESMO Open
Frontiers | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer | IntechOpen
